Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2004 Aug 1;64(15):5456-60.

Immunogenicity of constitutively active V599EBRaf.

Author information

1
Insitute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.

Abstract

Activating BRAF somatic missense mutations within the kinase domain are present in 60-66% of melanomas. The vast majority of these represent a single substitution of glutamate for valine (V599E). Here, we demonstrate spontaneous HLA-B*2705-restricted cytotoxic T-cell responses against an epitope derived from (V599E)BRaf. These T-cell responses were mutation specific as the corresponding epitope derived from wild-type BRaf was not recognized. The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patients with (V599E)BRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host.

PMID:
15289355
DOI:
10.1158/0008-5472.CAN-04-0937
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center